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key inflammatory markers (iNOS, MHCII, COX-2) and a re-
cruitment of microglia towards A  -burdened neurons. Us-
ing human AD brains, we showed alterations in the NGF met-
abolic pathway, which were mirrored in our tg rat model at 
early and late stages of amyloid plaque generation.  Conclu-
sion: A proinflammatory process and, consequently, the de-
regulation of the NGF metabolic pathway could be amongst 
the earliest pathological events in the progression of AD. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 It is becoming increasingly clear that Alzheimer’s dis-
ease (AD) neuropathology starts decades before the first 
clinical symptoms are manifested. Unfortunately, there 
are not, as yet, definitive biomarkers to predict the evolu-
tion of individuals from a noncognitively impaired (NCI) 
status to mild cognitive impairment (MCI) and AD  [1] . 
In addition, the study of human postmortem brains does 
not allow the identification of predictive biomarkers – 
even when the full characterization of the neuropathol-
ogy and cognitive status is available – as there is no un-
questionable evidence that a given subject categorized as 
NCI would necessarily evolve to MCI or AD. For this, 
new insights on the earliest stages of the amyloid pathol-
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 Abstract 
 Background: Alzheimer’s disease (AD) neuropathology like-
ly begins decades before clinical symptoms are manifested. 
Investigations on the early stages of the amyloid pathology 
are crucial for the discovery of diagnostic biomarkers or new 
therapeutic targets. Our transgenic (tg) animal models are 
most suitable to study early AD pathological events, as the 
pathology evolves in a well-staged manner, starting with in-
tracellular A  accumulation and ending with plaque deposi-
tion.  Objective: To determine the occurrence of key inflam-
matory markers and to look for signs of nerve growth factor 
(NGF) dysmetabolism at preplaque and postplaque stages in 
tg models of AD-like amyloid pathology and in human AD 
brains.  Methods: We used our own tg lines (mice and rat), 
high-quality human brain material and applied neurochem-
ical and immunohistochemical experimental approaches. 
 Results: In both tg models, we observed an intracellular ac-
cumulation of oligomeric A  in cortical and hippocampal 
pyramidal neurons. This coincided with an upregulation of 
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ogy are pivotal to the discovery of predictive biomarkers 
and new therapeutic targets.
 The above objectives could theoretically be attained by 
an in-depth investigation of the preclinical stages of indi-
viduals carrying familial AD genes. This is not an easy task 
given the limited number of such patients and the time re-
quired for solid conclusions. In this regard, transgenic (tg) 
animal models of the AD-like amyloid pathology are most 
suitable to unravel early AD pathological events. 
 Materials and Methods 
 We utilized the McGill-Thy1-APP mouse  [2] and the McGill-
R-Thy1-APP rat  [3] tg models of the AD-like amyloid pathology. 
Both models carry the human amyloid precursor protein (APP) 
transgene with familial AD mutations, resulting in extracellular 
plaque deposition, dystrophic neurites and a periplaque inflam-
matory process. We investigated the occurrence of key inflamma-
tory markers and the status of the proteins involved in the me-
tabolism of nerve growth factor (NGF) using a combination of 
neurochemical and immunohistochemical approaches as de-
scribed previously  [3, 4] . Whenever possible we have investigated 
biochemical alterations of the above markers in human AD brains 
from the Netherlands Brain Bank and from the Religious Orders 
Study, Rush Medical Center (Chicago, Ill., USA).
 Results and Discussion 
 We investigated features of the early AD-like amyloid 
pathology in our tg animals on the understanding that 
preplaque and the early extracellular amyloid plaque 
phase would clearly correspond to human preclinical 
stages, as has been eloquently highlighted by Ashe and 
Zahs  [5] . We observed that prior to the appearance of 
amyloid plaques there is an intracellular accumulation 
of A  oligomeric molecular forms in cortical and hip-
pocampal neurons. The systematic time-dependent 
analysis of the occurrence of intracellular A  -immuno-
reactive material, as investigated with an A  oligomer-
specific monoclonal antibody (Nu1)  [6] , and with a pep-
tide-oligomeric conformation-specific polyclonal anti-
body (OC)  [7] , suggested an evolution of this material 
towards a progressive intraneuronal accumulation of 
A  oligomers and later appearance of fibrillar A  mate-
rial, the latter largely disappearing as amyloid plaques 
emerged  [2] . The incremental intraneuronal accumula-
tion of A  -immunoreactive oligomeric species was co-
incidental with an upregulation of some key markers of 
inflammation such as iNOS, MHCII, IL-1  and COX2 
 [4, 8] and mobilization of resident microglial cells to-
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 Fig. 1. Schematic representation of the NGF metabolic pathway in 
normal brains and in AD.  a In normal brains, proNGF is released 
to the extracellular space by cortical pyramidal neurons along 
with the converstases and zymogens necessary for its processing 
to mNGF and its degradation. Briefly, plasminogen is converted 
to plasmin by tissue plasminogen activator (tPA) and plasmin 
cleaves proNGF into its mature form. The NGF molecules that are 
not retrogradely transported to the basal forebrain by projecting 
cholinergic neurons are degraded by MMP9. BFCN depend 
throughout life on the continuous endogenous supply of NGF for 
phenotype maintenance.  b In AD, the lack of trophic support to 
BFCN can be partly explained by a dramatic dysregulation in the 
expression and activity of the members of the NGF metabolic 
pathway. The presence of intracellular A  oligomers unleashes a 
proinflammatory reaction that negatively impacts on the regula-
tion of the NGF metabolic pathway. Plasminogen, tissue plasmin-
ogen activator and plasmin levels are reduced, explaining the par-
adoxical elevation of the NGF precursor in the presence of BFCN 
atrophy. The degradation of endogenous NGF levels is exacerbat-
ed, as MMP9 levels and activity are highly increased. 
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wards A  -burdened neurons of the cerebral cortex and 
hippocampus  [4] .
 Our laboratory identified the modality of CNS release 
of NGF; the precursor proNGF but not mature NGF 
(mNGF) is released in an activity-dependent manner. 
Furthermore, we described the metabolic pathway re-
sponsible for its maturation and degradation  [9] . There-
fore, we were interested in establishing whether an alter-
ation of this pathway could explain the well-known vul-
nerability of NGF-dependent basal forebrain cholinergic 
neurons (BFCN). The existence of BFCN atrophy in AD 
brains in the absence of detectable changes in the synthe-
sis of NGF  [10] and elevated levels of proNGF  [11] results 
in an apparent contradiction. We therefore investigated 
the levels and activity of the members of the NGF met-
abolic cascade in tg models and AD brains. In AD, we 
observed increased proNGF levels, decreased levels of 
plasminogen and tissue plasminogen activator and con-
sequently of plasmin, the protein responsible for the con-
version of proNGF to mNGF  [12] . Such a defect would be 
sufficient to explain the paradoxical elevation of proNGF 
as well as the cholinergic atrophy resulting from this tro-
phic disconnection. However, in AD, the situation is fur-
ther aggravated by the elevation of matrix metallopro-
teinase 9 (MMP9), the enzyme responsible for mNGF 
degradation  [12] . Interestingly, these biochemical chang-
es are even present at very early stages of the AD pathol-
ogy, as it has been observed that proNGF is already ele-
vated in MCI  [13] . Furthermore, we have also reported an 
elevation of the levels and zymographic activity of MMP9 
in MCI; changes that correlated with cognitive deteriora-
tion  [14] .
 We have recently found indications of a similar de-
regulation of the CNS NGF pathway in our McGill tg rat 
model. At late stages of the amyloid pathology, we have 
observed an increase in proNGF levels and MMP9 ac-
tivity. Interestingly, elevated levels of proNGF were also 
present at early stages of amyloid plaque generation  [15, 
16] . 
 Based on our studies in tg models, inflammation and 
NGF deregulation are early, connected components of 
the AD amyloid pathology ( fig. 1 ). Supporting this view, 
we have seen that injecting A  oligomers in the hippo-
campus of naïve rats is sufficient to unleash an inflam-
matory process as well as an elevation of proNGF  [12] . 
The application of the CNS anti-inflammatory agent mi-
nocycline is sufficient to correct both alterations at very 
early stages in mice tg models [ 12 ,  17 , Ferretti et al., in 
preparation].
 Conclusions 
 In brief, we have found a proinflammatory process at 
the earliest ‘preclinical’ stages of the AD-like amyloid 
pathology in tg models. We hypothesize that this early 
and previously unnoticed inflammation could unleash 
the deregulation of the NGF metabolic pathway; a pro-
cess which will ultimately lead to CNS BFCN atrophy 
 [18] . These pathological events might be amongst the 
earliest in the progression of AD and they could offer 
new insights for the identification of potential diagnos-
tic biomarkers or pharmacological targets for AD pre-
vention.
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